Lyrica
Product Images NDC 68258-7047

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 68258-7047). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 68258-7047-xx (Ndc 68258 7047 Xx Pfizer)

Lyrica 150 mg capsules label from Dispensing Solutions, Inc. The label shows the product name Lyrica with strength 150 mg and dosage form capsules. It includes prescribing information such as active ingredient pregabalin 150 mg per capsule, warning about habit forming, and directions to take orally. The label displays multiple barcodes, lot sample, and RX only designation. Manufacturer Pfizer Pharmaceuticals LLC is noted in bulk source data.*

FDA Label Image

Figure (Lyrica 01)

A text image displaying a formula for estimating creatinine clearance (CLCr). The formula calculates CLCr using age, weight, serum creatinine, and a correction factor for female patients (0.85).*

FDA Label Image

Chemical Structure (Lyrica 02)

Chemical structure diagram of the active ingredient in Lyrica, showing a molecular representation with an amino group, carboxyl group, and side chains consistent with pregabalin.*

FDA Label Image

Figure 1 (Lyrica 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo over increasing pain improvement percentages.*

FDA Label Image

Figure 2 (Lyrica 04)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline, depicting data for Pregabalin 100 mg three times a day versus placebo. The vertical axis shows percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Figure 3 (Lyrica 05)

Line chart showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses of 75 mg, 150 mg, and 300 mg taken twice daily compared to placebo. The chart compares efficacy outcomes across these dosing groups.*

FDA Label Image

Figure 4 (Lyrica 06)

A line chart depicting percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The chart shows trends of patient improvement across different pain reduction percentages.*

FDA Label Image

Figure 5 (Lyrica 07)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline, comparing pregabalin 100 mg three times a day, pregabalin 50 mg three times a day, and placebo. The graph shows trends of patient improvement over a range of pain improvement percentages.*

FDA Label Image

Figure 6 (Lyrica 08)

A bar chart comparing responder rates (%) across different studies (E1 and E3) with treatments including placebo and various dosages of a drug. The x-axis shows treatment groups and sample sizes (N), while the y-axis shows response rates from 0% to 60%. Percentages are displayed above each bar, showing higher responder rates in drug groups versus placebo in both studies.*

FDA Label Image

Figure 7 (Lyrica 09)

A line graph showing seizure reduction as median percent change from baseline versus dose (mg/day) for Lyrica across four studies (E1BD, E2TID, E3BD, E3TID). Each study is represented by a different symbol, with seizure reduction increasing with dose up to 600 mg/day. Significant p-values (≤ 0.0001) indicate dose-dependent efficacy trends in all studies.*

FDA Label Image

Figure 8 (Lyrica 10)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Lyrica (pregabalin) at daily doses of 300 mg, 450 mg, 600 mg, and placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percent of patients improved, with lines comparing different doses and placebo response.*

FDA Label Image

Figure 9 (Lyrica 11)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR (Likely a clinical event) over days. Two groups are shown: Pregabalin and Placebo, with the Pregabalin group maintaining a higher percentage of subjects without LTR over the 180 days than the Placebo group.*

FDA Label Image

Figure 10 (Lyrica 12)

A line graph comparing the percent of subjects improved on the y-axis to the percent improved from baseline to week 12 BOCF on the x-axis. It features two lines: one solid line for Pregabalin and one dashed line for Placebo, showing higher improvement percentages generally for Pregabalin across the range.*

FDA Label Image

Figure 11 (Lyrica 13)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo groups. The x-axis shows percent improvement from baseline to week 16 BOCF, ranging from >0 to 100. The y-axis shows the percent of subjects improved, ranging from 0 to 100%. Two lines represent the Pregabalin group (solid line) and Placebo group (dashed line), showing greater improvement with Pregabalin across different improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.